In last trading session, Lineage Cell Therapeutics Inc (AMEX:LCTX) saw 0.4 million shares changing hands with its beta currently measuring 1.26. Company’s recent per share price level of $0.92 trading at $0.06 or 6.75% at ring of the bell on the day assigns it a market valuation of $173.73M. That closing price of LCTX’s stock is at a discount of -75.0% from its 52-week high price of $1.61 and is indicating a premium of 16.3% from its 52-week low price of $0.77. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.4 million shares which gives us an average trading volume of 563.20K if we extend that period to 3-months.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Upright in the green during last session for gaining 6.75%, in the last five days LCTX remained trading in the red while hitting it’s week-highest on Monday, 09/23/24 when the stock touched $0.92 price level, adding 5.15% to its value on the day. Lineage Cell Therapeutics Inc’s shares saw a change of -15.60% in year-to-date performance and have moved -2.13% in past 5-day. Lineage Cell Therapeutics Inc (AMEX:LCTX) showed a performance of 6.95% in past 30-days. Number of shares sold short was 15.63 million shares which calculate 39.8 days to cover the short interests.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Statistics highlight that Lineage Cell Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -37.84% of value to its shares in past 6 months, showing an annual growth rate of -25.00% while that of industry is 17.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -41.60% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.03M for the same. And 6 analysts are in estimates of company making revenue of 1.32M in the next quarter. Company posted 1.25M and 2.09M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.25% during past 5 years.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Insiders are in possession of 0.44% of company’s total shares while institution are holding 50.31 percent of that, with stock having share float percentage of 50.53%. Investors also watch the number of corporate investors in a company very closely, which is 50.31% institutions for Lineage Cell Therapeutics Inc that are currently holding shares of the company. BROADWOOD CAPITAL INC is the top institutional holder at LCTX for having 41.67 million shares of worth $41.55 million. And as of 2024-06-30, it was holding 22.7798 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 9.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.2264 of outstanding shares, having a total worth of $9.53 million.
